Abstract
The normal function of the immune system involves a myriad of synergistic interactions among cytokines of many types (e.g. lymphokines, monokines and thymic hormones). It seems then eminently logical that efforts to modify immune function with exogenous cytokines should involve the employment of combinations. It will be the intent of this chapter to summarize our recent efforts to employ combination therapy to restore and direct the thymus-dependent T cell system.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Bibliography
K. Komuro and E.A. Boyse, Induction of T lymphocytes from precursor cells in vitro by a product of the thymus, J. Exp. Med. 138: 479–484 (1973).
A.L. Goldstein, Ed., “Thymic hormones and lymphokines”, Plenum Press, New York (1984).
S.S. Chen, J.S. Tung, S. Gillis, R.A. Good and J.W. Hadden, Changes in surface antigens of immature thymocytes under the influence of T cell growth factor and thymic factors, Proc. Natl. Acad. Sci. 80: 5980–5984 (1983).
P. Andrews, K. Shortman, R. Scollay, E.F. Potworowski, A.M. Kruisbeek, G. Goldstein, N. Trainin and J-F. Bach, Thymus hormones do not induce proliferative ability or cytolytic function on PNA+ cortical thymocytes. Cell. Immunol. 91: 455–466 (1985).
P.J. Conlon, C.S. Henney and S. Gillis, Cytokine-dependent thymocyte responses, J. Immunol. 128: 797–804 (1982).
J.W. Hadden, S. Specter and E.M. Hadden, Effects of T cell growth factor (interleukin 2) and thymic hormones on prothymocytes and immature thymocytes, Lymph. Res. 5: 49–54 (1986).
W. Falk, B. Kyewski, D. Mannel and P.H. Kramer, Growth of double negative mouse thymocytes is initiated by the combined action of interleukin I and interleukin 2, Lymph. Res. 6: 75 (1987).
J.W. Hadden, H. Chen, Y. Wang and E.M. Hadden, Strategies of immune reconstitution: effects of lymphokines on murine T cell development in vitro and in vivo, Life Sci. AIDS Comm. 44: 5–12 (1989).
J.W. Hadden, Thymic endocrinology, Int. J. Immunopharmacol. 14: 345–352 (1992).
P.T. Le, L. W. Vollger, B.F. Haynes and K.H. Singer, Ligand binding to the LFA-3 cell adhesion molecule induces IL-1 production by human thymic epithelial cells, J. Immun. 144: 4541–4547 (1990).
M. Wiranowska, T. Kaido, G. Caspritz, J. Cook and J.W. Hadden, Interleukin-2 and coculture with thymic epithelial cells synergistically induce prothymocyte differentiation and proliferation, Thymus 10: 231–235 (1987).
S.M. Denning, J. Kurtzburg, P.T. Le, D.T. Tuck, K.H. Singer and B.F. Haynes, Human thymic epithelial cells directly induce activation of autologous immature thymocytes, Proc. Natl. Acad. Sci. 85: 3125–3129 (1988).
A. Galy, E.M. Hadden, J-P. Touraine and J.W. Hadden, Effects of cytokines on human thymic epithelial cells in culture: IL1 induces thymic epithelial cell proliferation and change in morphology, Cell Immunol. 124: 13–27 (1989).
A. Galy, C.A. Dinarello, T.S. Kupper and J.W. Hadden, Production of cytokines by recombinant ILl-stimulated human thymic epithelial cells in vitro, Cell Immunol. 129: 161–175, (1990).
J.A. Coto, E.M. Hadden, M. Sauro, N. Zorn and J.W. Hadden, Interleukin 1 regulates secretion of zinc-thymulin by thymic epithelial cells and its action on T lymphocyte proliferation and nuclear protein kinase C, Proc. Natl. Acad. Sci. (1992, in press).
M.B. Sztein, S.R. Serrate and A.L. Goldstein, Modulation of interleukin 2 receptor expression on human lymphocytes by thymic hormones, Proc. Natl. Acad. Sci. 83: 6107–6111 (1986).
E.M. Hadden, P. Malec, M. Sosa and J.W. Hadden, Mixed interleukins and thymosin fraction V synergistically induce T lymphocyte development in hydrocortisone-treated aged mice, Cell. Immunol. (1992, in press).
E. Mocchegiani and N. Fabris, “In vivo” and “in vitro” effect of zinc on thymic efficiency in old age, in: “Abstracts of 6th Int. Cong. of Int. Assoc. Biol. Gerontol.”, Ancona, Italy, (1991).
J.W. Hadden, E.M. Hadden, P. Baekey, P. Skipper and J.N. Endicott, Adjuvant nonrecombinant interleukins and contra-suppressive agents induces immune regression in head and neck cancer, Arch. Otolaryngol. (1992, in press).
N.T. Berlinger, E.Y. Hilal, H.F. Oettgen and R.A. Good, Deficient cell-mediated immunity in head and neck cancer patients secondary to autologous suppressive immune cells, Laryngoscope 88: 470–481 (1978).
G.T. Wolf, Head and neck tumor immunology, in: “Immunobiology, Histophysiology and Tumor Immunology in Otolaryngology”, Proc. 2nd Int. Acad. Conf., Utrecht, The Netherlands, (1987).
H.J. Wanebo, T. Jones, R. Pace, R. Cantrell and P. Levine, Immune restoration with interleukin-2 in patient with squamous cell carcinoma of the head and neck, Amer. J. Surg. 158: 356–360 (1989).
D. Berd, H.C. Maguire and M.J. Mastrangelo, Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide, Cancer Res. 44: 5439–5443 (1984).
D. Berd, H.C. Maguire Jr., P. McCue and M.J. Mastrangelo, Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients, J. Clin. Oncol. 8: 1858–1867 (1990).
M.S. Mitchell, R.A. Kempf, W. Harel, H. Shau, W.D. Boswell, S. Lind, G. Dean, J. Moore and E.C. Bradley, Efficacy of low-dose cyclophosphamide and interleukin-2 in melanoma, in: “Advances in Immunopharmacology 4”, J.W. Hadden, F. Spreafico, Y. Yamamura, K.F. Austen, P. Dukor and K. Masek, eds, Pergamon Press, Oxford (1989).
J.H.L. Playfair and A.W. Heath, Cytokines–The new generation of adjuvants for vaccines?, in: “Immunotherapeutic prospects of infectious diseases”, K.N. Masihi and W. Lange, eds., Springer-Verlag, Berlin, (1990).
K. Kelly, Harvey, Sadler and D. D.monde, Accelerated cytodifferentiation of antibody-secreting cells in Guinea pig lymph nodes stimulated by sheep erythrocytes and lymphokines, Clin. Exp. Immunol. 21: 141–154 (1975).
M.S. Pulley, V. Nagendran, J.M. Edwards, D.C. Dumonde, Intravenous, intralesional and endolymphatic administration of lymphokines in human cancer, Lymph. Res. 5: S157–S163, (1986).
G. Cortesina, A. DeStefani, M. Giovarelli, M.G. Barioglio, G.P. Cavallo, C. Jemma and G. Forni, Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically, Cancer 62: 2482–2485, (1988).
G. Cortesina, A. DeStefani, E. Galeazzi, M. Bussi, C. Giordano, G.P. Cavallo, C. Jemma, S. Vai, G. Forni and G. Valente, The effect of preoperative local interleukin-2 (IL-2) injections in patients with head and neck squamous cell carcinoma, Acta. Otolaryngol. 111: 428–433 (1991).
V. Mattijssen, P.H. DeMulder, J.H. Schornagel, J. Verweij, P. Van den Broak, A. Galazka, S. Roy and D.J. Ruiter, Clinical and immunopathological results of a phase II study of perilymphatically injected recombinant interleukin 2 in locally far advanced, nonpretreated head and neck squamous cell carcinoma, J. Immunother. 10: 63–68 (1991).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Hadden, J.W., Malec, P., Saha, A., Hadden, E.M. (1993). Cytokine Synergy in Immunotherapy. In: Garaci, E., Goldstein, A.L. (eds) Combination Therapies 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2964-4_1
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2964-4_1
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6289-0
Online ISBN: 978-1-4615-2964-4
eBook Packages: Springer Book Archive